argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Guidelines aim to establish state-regulated veterinary blood banks
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
This project shall be implemented through incorporation of a new joint venture company in Zambia
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Inclacumab was generally well tolerated in THRIVE-131
Subscribe To Our Newsletter & Stay Updated